Treats Attention Deficit Hyperactivity Disorder (ADHD). Sold as Xelstrym. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Dextroamphetamine (sold as Xelstrym), first approved Mar 22, 2022, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2024 | Change | Beneficiaries |
|---|---|---|---|---|
| Dextroamphetamine Sulfate | Part D | $4.7M | -9% | 9,458 |
| Dextroamphetamine Sulfate ER | Part D | $4.7M | -30% | 6,001 |
| Dexedrine | Part D | $509K | -78% | 73 |
| Zenzedi | Part D | $281K | -27% | 137 |
| Xelstrym | Part D | $200K | +292% | 131 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Mar 22, 2022 | XelstrymNDA 215401 ยท New dosage form | Noven Pharms Inc | 5 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA
